Iniparib (BSI-201)

Iniparib is the United States Adopted Name (USAN) for a novel investigational anticancer agent being studied in multiple cancers, including Phase II and Phase III clinical trials in breast, lung and ovarian cancers. Iniparib is the subject of an extensive translational and research program designed to better define the mechanism of anti cancer action of iniparib and to identify biomarkers predictive of response both within and across tumor types.